J&J Could Pay Ollin’s Backers $2.2 Billion Upfront
Under the deal, J&J could pay Ollin’s backers $2.2 billion upfront in cash, plus $1.2 billion in potential milestone payments.
Story updates
12:11:39 AM UTC
SquawkNews
Johnson & Johnson NYSE:JNJ is poised to buy privately held eye disease drug developer Ollin Biosciences for up to $3.4 billion, the Financial Times reported on Sunday, citing people familiar with the matter.Under the terms of the deal being discussed, J&J could pay Ollin’s backers $2.2 billion upfr…